Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody
By R. Bargou, E. Leo, G. Zugmaier, M. Klinger, M. Goebeler, S. Knop, R. Noppeney, A. Viardot, G. Hess, M. Schuler and 10 more. Science, 2008
1,094 citations recorded by the source corpus.
Subfields: Immunology, Oncology, Radiology, Nuclear Medicine and Imaging
View Paper: https://www.semanticscholar.org/paper/955d1ef9c4a39d3bd12022501b2b824e33d43c70
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
In Oncology
In Radiology, Nuclear Medicine and Imaging
Citations in the corpus
- Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. (2018, background): “Similar neurologic events have been observed with other CD19-directed therapies,(27-29) in other T-cell-activating studies,(30) and in blinatumomab studies in relapsed/refractory ALL and non-Hodgkin’s lymphoma.(18,22,24) The pathogenesis of neurologic events is poorly understood and does not seem to”
- Therapeutic antibodies for autoimmunity and inflammation (2010, methodology): “Blinatumomab (MT103; Micromet/MedImmune), a BiTE specific for CD19 and CD3, has been used to treat patients with non-Hodgkin's lymphom”
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia (2013, neutral): “Her baseline karyotype was 46,XX,del(1)(p13),t(2;9)(q?21;q?21), t(3;17)(p24;q23),del(6)(q16q21),del(9)(q13q22), der(16)t(1;?;16)(p13;?p13.”
- Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies (2014, neutral): “In the first clinical trial of blinatumomab, efficacy was demonstrated in adults with refractory lymphomas, with a 35% objective response rate.(3) In a phase 2 study of adults with minimal residual disease–positive ALL, 16 of 21 patients became negative for minimal residual disease.”
- Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing (2017, background): “Therapies that direct T cells to tumors, including adoptive transfer of genetically engineered T cells and T cell-dependent bispecific antibodies (TDBs) that selectively recruit T cells to tumor cells have been clinically validated in the treatment of B cell leukemias and lymphomas (Bargou et al., 2”
- Biology, risk stratification, and therapy of pediatric acute leukemias: an update. (2011, background): “Among many novel therapeutics under investigation (Table 4),(101) killer-cell immunoglobulin-like receptor– mismatch natural cell therapy(120,121) and immunotherapy with a T-cell–engaging CD19-/CD3-bispecific antibody construct (blinatumomab) seem to be particularly promising.(122)”
- Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. (2011, methodology): “The dosing schedule was based on the data in relapsed NHL, which had shown elimination of tumor cells from bone marrow at a dose of 15 g/m(2)/24 hours administered as continuous intravenous infusion over 4 to 8 weeks.(11) In patients, with an allogeneic donor, an allogeneic HSCT was offered at any t”